Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. (Nasdaq: XCUR) on December 30, 2022. The filing primarily addresses significant changes to the composition of the Board of Directors and the Company's compliance status with Nasdaq listing rules regarding the Audit Committee.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, or margin data. However, it references recent capital raising activities:
- May 2022 Private Placement: Issued 818,299 shares at $5.81 per share, resulting in net proceeds of approximately $4.9 million.
- September 2022 Private Placement: Agreed to issue 3,400,000 shares at $1.60 per share. Expected gross proceeds are approximately $5.4 million, with closing expected by January 20, 2023.
Material Changes
Effective December 30, 2022, the following governance changes occurred:
- Resignations: James Sulat and Bali Muralidhar, M.D., Ph.D., resigned from the Board of Directors and their respective committee assignments.
- Board Size Reduction: The Board size was decreased from five to four directors.
- New Appointment: Jiyoung Hwang was appointed to the Board as a Class II director (term expiring 2025) representing CBI USA, Inc. She is not considered an independent director and will not serve on any committees.
- Committee Reassignments: Jeffrey L. Cleland, Ph.D., was appointed to the Audit Committee, and Elizabeth Garofalo, M.D., was appointed to the Nominating and Corporate Governance Committee.
Outlook, Risks, and Contingencies
Nasdaq Compliance Status: The Company is currently non-compliant with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to be comprised of three independent directors. The committee currently consists of only two independent directors (Dr. Cleland and Dr. Garofalo).
Cure Period: The Company is entitled to a cure period to regain compliance until the earlier of its next annual meeting of stockholders or one year from the date of non-compliance. Management expects to be compliant by the end of this period.
Risks: Forward-looking statements are subject to risks including the ability to consummate the September 2022 Private Placement, satisfaction of closing conditions, potential litigation, and the ability to regain Nasdaq compliance within the cure period.
Investor Verification Checklist
- Verify the closing status and final proceeds of the September 2022 Private Placement with CBI USA.
- Monitor the Company's progress in appointing a third independent director to the Audit Committee to satisfy Nasdaq Listing Rule 5605(c)(2)(A).
- Review the definitive proxy statement (Schedule 14A) for details on the non-employee director compensation policy applicable to the new appointee.
- Confirm the Company's cash position and runway given the recent dilution and the timing of the expected $5.4 million proceeds.